FDA approves Progenics' drug for rare tumors

The drug, Azedra, was approved to treat patients above the age of 12 who have either of the two tumors, pheochromocytoma or paraganglioma, and require anti-cancer therapy
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news

Related Links:

We present a case of extraskeletal paravertebral lesion detected in a known case of breast cancer with increased Ga-DOTANOC uptake later proved to be hemangioma. This is a novel finding and should be kept as a rare benign differential in evaluation of lesions with somatostatin receptor expression. PMID: 30829863 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Clin Nucl Med Source Type: research
Cancers, Vol. 11, Pages 225: The Value of Histological Algorithms to Predict the Malignancy Potential of Pheochromocytomas and Abdominal Paragangliomas—A Meta-Analysis and Systematic Review of the Literature Cancers doi: 10.3390/cancers11020225 Authors: Adam Stenman Jan Zedenius Carl Christofer Juhlin Pheochromocytomas (PCCs) and abdominal paragangliomas (PGLs), collectively abbreviated PPGLs, are neuroendocrine tumors of the adrenal medulla and paraganglia, respectively. These tumors exhibit malignant potential but seldom display evidence of metastatic spread, the latter being the only widely accepted ev...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Bancos Young Metastatic pheochromocytoma and paraganglioma (PPGL) are incurable neuroendocrine tumors. The goals of treatment include palliating symptoms and reducing tumor burden. Little is known about the use of radiofrequency ablation (RFA), cryoablation (CRYO), and percutaneous ethanol injection (PEI) to treat metastatic PPGL. We performed a retrospective study of patients age 17 years and older with metastatic PPGL who were treated with ablative therapy at Mayo Clinic, USA, between June 14, 1999 and November 14, 2017. Our outcomes measures were radiographic response, procedure-related complications, and sympto...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
acute; R, Faggiano A, Schlumberger M, Borson-Chazot F, Mannelli M, Gimenez-Roqueplo AP, Caron P, Timmers HJLM, Fassnacht M, Robledo M, Borget I, Baudin E, European Network for the Study of Adrenal Tumors (ENS@T) Abstract Background: Malignant pheochromocytoma and paraganglioma (MPP) are characterized by prognostic heterogeneity. Our objective was to look for prognostic parameters of overall survival in MPP patients. Patients and Methods: Retrospective multicentric study of MPP characterized by a neck-thoraco-abdomino-pelvic CT or MRI at the time of malignancy diagnosis in European centers between 1998 and 201...
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: J Clin Endocrinol Metab Source Type: research
nst Peter H.L.T. Bisschop Koen M.A. Dreijerink Marieke F. van Dooren Frederik J. Hes Jeroen C. Jansen Eleonora P.M. Corssmit Erik F. Hensen Germline mutations in succinate dehydrogenase subunit B and D (SDHB and SDHD) are predisposed to hereditary paraganglioma (PGL) and pheochromocytoma (PHEO). The phenotype of pathogenic variants varies according to the causative gene. In this retrospective study, we estimate the mortality of a nationwide cohort of SDHB variant carriers and that of a large cohort of SDHD variant carriers and compare it to the mortality of a matched cohort of the general Dutch population...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Skogseid Karel Pacak Adrenocortical carcinoma (ACC) and pheochromocytoma and paraganglioma (PPGL) are defined by clinicopathological criteria and can be further sub-divided based on different molecular features. Whether differences between these molecular subgroups are significant enough to re-challenge their current clinicopathological classification is currently unknown. It is also not fully understood to which other cancers ACC and PPGL show similarity to. To address these questions, we included recent RNA-Seq data from the Cancer Genome Atlas (TCGA) and Therapeutically Applicable Research to Generate Effective Tr...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
AbstractThe past decade has witnessed a growing role and increasing use of whole-body magnetic resonance imaging (WB-MRI). Driving these successes are developments in both hardware and software that have reduced overall examination times and significantly improved MR imaging quality. In addition, radiologists and clinicians have continued to find promising new applications of this innovative imaging technique that brings together morphologic and functional characterization of tissues. In oncology, the role of WB-MRI has expanded to the point of being recommended in international guidelines for the assessment of several can...
Source: La Radiologia Medica - Category: Radiology Source Type: research
menez-Roqueplo AP Abstract PURPOSE: Pheochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumors. While most PPGL are benign, up to 20% may become metastatic with SDHB- and FH-mutated tumors showing the higher risk. We aimed at determining the contribution of immortalization mechanisms to metastatic progression. EXPERIMENTAL DESIGN: Immortalization mechanisms were investigated in 200 tumors. To identify telomerase (+) tumors we analyzed genomic alterations leading to transcriptional activation of TERT comprising promoter mutations, hypermethylation and gain copy number. To identify tumors that a...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Pheochromocytomas (PCCs) and paragangliomas (PGLs) are the most heritable endocrine tumors. Genetic testing for 12 driver susceptibility genes is recommended in all PCC and PGL cases. However, detection of som...
Source: Molecular Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research
The Food and Drug Administration on Tuesday approved the first ever non-surgical treatment for the rare neuroendocrine cancers: pheochromocytoma and paraganglioma. The approval for Azedra, a drug developed by Progenics Pharmacecuticals of Tarrytown, N.Y., was based on a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania in Philadelphia. “This is a true breakthrough," said Dr. Daniel A. Pryma, an associate professor of radiology and radiation…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Therapy | Paraganglioma | Pheochromocytoma